Last Posted: Aug 06, 2020
- Limited Practical Utility of Liquid Biopsy in the Treated Patients with Advanced Breast Cancer.
Niwinska Anna et al. Diagnostics (Basel, Switzerland) 2020 Jul 10(8) - Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
SV Bratman et al, Nature Cancer, August 2020 - Methylation extends the reach of liquid biopsy in cancer detection
W Li et al, Nat Rev Clin Oncol, July 31, 2020 - Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
Liu Eric et al. The oncologist 2019 24(6) 783-790 - Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project.
De Gregorio Amelie et al. Archives of gynecology and obstetrics 2020 301(1) 273-281 - Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review.
Esagian Stepan M et al. Journal of cancer research and clinical oncology 2020 Aug 146(8) 2051-2066 - Indications of next-generation sequencing in non-Hodgkin's lymphoma.
Heimann Pierre et al. Current opinion in oncology 2020 Jul - Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th Edition.
Ebi Hiromichi et al. Cancer science 2020 Jul - Next-Generation Sequencing of Plasma Cell-Free DNA for Treatment Monitoring in Advanced Head and Neck Cancer Patients.
Bai Jing et al. Clinical laboratory 2020 Jul 66(7) - Circulating biomarkers predictive of tumor response to cancer immunotherapy.
Lee Ernest Y et al. Expert review of molecular diagnostics 2019 19(10) 895-904
.png)
No hay comentarios:
Publicar un comentario